CBSC (Cardiac Biotech Solutions) Revenue: $0.06 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiac Biotech Solutions Revenue?

Cardiac Biotech Solutions CBSC Revenue is $0.06 Mil as of Jun. 2025.

Cardiac Biotech Solutions's revenue for the three months ended in Jun. 2025 was $0.05 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2025 was $0.06 Mil. Cardiac Biotech Solutions's Revenue per Share for the three months ended in Jun. 2025 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Cardiac Biotech Solutions  (OTCPK:CBSC) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Cardiac Biotech Solutions Revenue Related Terms

Cardiac Biotech Solutions Revenue Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions Revenue Chart

Cardiac Biotech Solutions Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Revenue
0.03 0.08 0.08 0.14 0.04

Cardiac Biotech Solutions Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.00 0.05

CBSC vs LUCY, NXGL, MHUAF: Revenue Comparison

For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiac Biotech Solutions Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's Revenue distribution charts can be found below:

* The bar in red indicates where Cardiac Biotech Solutions's Revenue falls into.


Cardiac Biotech Solutions Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.06 Mil mean?
Cardiac Biotech Solutions (CBSC) has a Revenue of $0.06 Mil as of Jun. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' Revenue too high?
Cardiac Biotech Solutions' current Revenue is $0.06 Mil.
How does Cardiac Biotech Solutions' Revenue compare to LUCY and NXGL?
Cardiac Biotech Solutions' Revenue of $0.06 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current Revenue is $0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current Revenue of $0.06 Mil. The current Revenue is $0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Revenue is $0.06 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.